Abstract
Introduction:
ABP 798 (rituximab-arrx, RIABNI®) is a biosimilar to rituximab available as a sterile, preservative-free solution (10 mg/mL) in a single-use vial for intravenous (IV) infusion. The purpose of this study was to assess the physicochemical stability of ABP 798 after dilution with 0.9% (w/v) saline or 5% (w/v) dextrose.
Methods:
Two experimental arms designated “preliminary hold” and “optimized storage condition” were assessed. For both arms, ABP 798 was diluted to 1 and 4 mg/mL with sterile 0.9% (w/v) saline or 5% (w/v) dextrose in IV bags. For the preliminary hold assessment, the IV bags were kept at 2°C to 8°C for up to 30 days, followed by storage at 30°C for 24 hours (h), and then infusion at ambient temperature. For the optimized storage condition assessment, the IV bags were kept at 2°C to 8°C for up to 30 days (saline-diluted) or up to 24 hours (dextrose-diluted), followed by storage at 30°C (saline-diluted) or 25°C (dextrose-diluted) for 24 hours and infusion at two different infusion rates. Samples collected at different time points were evaluated for various product quality attributes.
Results:
Saline-diluted ABP 798 was physicochemically stable after 30 days of storage at 2°C to 8°C followed by storage at 30°C for 24 hours, and then infusion, as determined by the absence of changes to quality attributes. Degradation was observed in dextrose-diluted ABP 798 after 30 days of storage at 2°C to 8°C followed by 24 hours storage at 30°C. Dextrose-diluted ABP 798 remained physicochemically stable after 24 hours storage at 2°C to 8°C followed by 24 hours at 25°C.
Conclusions:
These results indicate that ABP 798 remains chemically and physically stable when diluted in IV bags with 0.9% (w/v) saline stored at 2°C to 8°C for 30 days or 5% (w/v) dextrose stored at 2°C to 8°C for 1 day. Overall, these findings provide strong evidence supporting the chemical and physical stability of ABP 798 under the tested conditions. It is essential for the end-user to ensure the overall quality of the prepared admixture by strictly adhering to the product’s packaging insert instructions.
Get full access to this article
View all access options for this article.
